Free Daily Podcast Summary
The BioHub - by Avetix: Daily Summaries Delivered
by Max Brennan - Biotech HeadHunter
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday20 min
Episode 189 - Cameron Pitt - Co-founder & COO Quanta Therapeutics
In this episode of The BioHub Podcast, Max sits down with Cameron Pitt, Co-Founder and COO of Quanta Therapeutics.Cameron's career has taken him from academic research at Stanford and UCSF, to venture investing at Versant Ventures and Sofinnova Investments, before helping form and build Quanta Therapeutics from the ground up.Quanta is focused on one of the biggest challenges in oncology: targeting RAS-driven cancers. Using a novel approach designed to restore control of RAS signalling, the company is developing therapies aimed at addressing a broad range of RAS-driven tumours.In this conversation, we discuss Cameron's transition from academia to venture capital and company building, the science behind Quanta, the realities of building a biotech company, and how the team is thinking about growth and fundraising in today's market.
- 5 days ago30 min
Episode 188 - Geert Kersten - CEO of CEL-SCI
In this episode of The BioHub Podcast, Max sits down with Geert Kersten, Chairman and CEO of CEL-SCI Corporation.Geert has led CEL-SCI for nearly three decades, overseeing the development of the company's lead immunotherapy candidate, Multikine, and navigating one of the longest and most challenging journeys in biotech.In this conversation, we discuss the realities of building a biotech company over the long term, the persistence required to advance innovative therapies, and Geert's perspective on today's biotech market.We also explore CEL-SCI's recent clinical progress, the company's long-term vision, and the lessons Geert has learned from spending almost 30 years at the helm of a public biotech company.
- 6 days ago27 min
Episode 187 - Leonard Mazur - CEO Citius Pharma
In this episode of The BioHub Podcast, Max sits down with Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals.Leonard is a seasoned entrepreneur and pharmaceutical executive who has spent decades building, scaling, and commercializing healthcare companies. Throughout his career, he has founded multiple successful businesses, led major transactions, and helped bring innovative therapies to patients across a range of therapeutic areas.In this conversation, we discuss Leonard's journey as a serial entrepreneur, the lessons he's learned from building companies from the ground up, and the importance of combining strong science with commercial strategy.We also explore the evolution of Citius Pharmaceuticals, the company's recent milestones, the challenges of navigating today's biotech market, and Leonard's advice for the next generation of biotech founders and leaders.
- 1 weeks ago35 min
Episode 186 - Derek Small - Founder, Managing Director Luson Bioventures
In this episode of The BioHub Podcast, Max sits down with Derek Small, Founder and Managing Director of Luson Bioventures.Over the past two decades, Derek has built a reputation as one of biotech's leading venture creators, founding and leading multiple companies across neuroscience and CNS drug development. Through Luson, he has helped launch, finance, and scale businesses from inception, raising more than $1 billion in capital along the way.In this conversation, we discuss the differences between venture creation and traditional venture capital, why neuroscience remains one of the most exciting areas in biotech, and what it takes to build successful companies through changing market cycles.We also explore capital efficiency, company building in today's environment, and the lessons Derek has learned from founding and leading biotech companies over the last twenty years.
- 1 weeks ago24 min
Episode 185 - Ed Ahn - Medipost INC
Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modification.Edward leads MEDIPOST's U.S. operations and global expansion efforts for CARTISTEM®, the world's first approved allogeneic stem cell therapy derived from umbilical cord blood. Since its approval in South Korea, CARTISTEM has been used to treat more than 30,000 patients, and under Edward's leadership the company is now advancing late-stage clinical development in the United States, with one of the most ambitious regenerative medicine programs in orthopedics today.What makes Edward's perspective particularly interesting is his focus on the practical realities of turning breakthrough science into scalable healthcare solutions. He has championed a strategy that combines clinical development, manufacturing infrastructure, regulatory execution, and long-term commercialization planning from day one. That vision has included building a North American presence, forming strategic manufacturing partnerships, and creating the operational foundation required to bring advanced cell therapies to patients around the world.As regenerative medicine moves from promise to reality, Edward has become a leading voice on how biotechnology companies can successfully navigate the path from scientific innovation to global commercialization. His work sits at the intersection of stem cell science, healthcare innovation, manufacturing strategy, and venture-backed growth—areas that will define the next generation of medicine.
- 1 weeks ago29 min
Episode 184 - Randy Teel - President & CEO Arvinas
In this episode of The BioHub Podcast, Max sits down with Randy Teel, President and CEO of Arvinas.Randy joined Arvinas in 2018 as Vice President of Corporate Development and has since helped guide the company through a period of significant growth, ultimately stepping into the CEO role. Today, Arvinas is one of the pioneers in targeted protein degradation, using its PROTAC platform to develop therapies designed to eliminate disease-causing proteins.In this conversation, we discuss Randy’s journey from strategy and corporate development into the CEO seat, the evolution of Arvinas from an emerging platform company to an industry leader, and the challenges of building and scaling a biotech company.We also explore the future of targeted protein degradation, the company’s unique partnership approach, and what’s next for Arvinas and its pipeline.
- 2 weeks ago25 min
Episode 183 - Matt Erick - CCO Biocon Biologics
Matt Erick, Chief Commercial Officer for Advanced Markets at Biocon Biologics, joins Max on The BioHub Podcast.With more than two decades of experience across pharma, biologics, distribution, and healthcare services, Matt has helped shape commercial strategy across some of the industry's most complex and competitive markets.In this conversation, we discuss Biocon's expansion into the U.S., the integration of its generics and biosimilars businesses, the evolution of the biosimilars market, and the role these medicines play in improving patient access worldwide.We also explore the challenges of navigating policy and regulatory change, building long-term commercial strategies, and driving growth in a challenging market environment.
- 2 weeks ago23 min
Episode 182 - David Solomon - CEO of Thalia Therapeutics
We were delighted to be joined by Dr. David Solomon, Chief Executive Officer of Thalia Therapeutics, onto The BioHub!David brings more than three decades of leadership experience across the biotechnology, pharmaceutical, and healthcare sectors, having led multiple publicly listed and private biotech companies throughout Europe and the United States. Throughout his career, he has played a key role in advancing innovative therapies, scaling organisations, securing major strategic partnerships, and delivering significant shareholder value.Prior to joining Thalia Therapeutics, David served as CEO of companies including Zealand Pharma, where he led the business through its IPO and the global approval of its lead GLP-1 therapy, and Silence Therapeutics, helping position the company as a leading player in the RNA therapeutics space. He has also held numerous board positions and remains a highly respected figure across the global biotech ecosystem.At Thalia Therapeutics, David is leading the company’s strategic focus on next-generation RNA therapeutics and novel delivery technologies, with ambitions to address major unmet needs across cardiovascular disease, oncology, and beyond.
About The BioHub - by Avetix
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The BioHub - by Avetix in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The BioHub - by Avetix daily summary?
It's a free AI-powered email that summarizes new episodes of The BioHub - by Avetix as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The BioHub - by Avetix podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The BioHub - by Avetix product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Max Brennan - Biotech HeadHunter.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The BioHub - by Avetix release new episodes?
The BioHub - by Avetix publishes daily. Our AI generates a summary within hours of each new episode.
What topics does The BioHub - by Avetix cover?
The BioHub - by Avetix covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The BioHub - by Avetix summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.